Form 4: Apellis Pharmaceuticals Executive Exercises Stock Options

Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options on May 21, 2025, acquiring 12,780 shares of common stock.

Summary

• On May 21, 2025, Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, exercised stock options to acquire 12,780 shares of common stock at a price of $3.76 per share.
• Following this transaction, Deschatelets directly owns 1,160,496 shares of Apellis Pharmaceuticals common stock.
• The stock options were granted on February 8, 2016, and are fully vested.

Sentiment

Score: 5

Explanation: This is a neutral event, simply reflecting the exercise of previously granted stock options. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is a routine exercise of stock options.

Key Dates

Keywords

Apellis Pharmaceuticals, Pascal Deschatelets, stock options, Form 4, insider trading, beneficial ownership, APLS, Chief Scientific Officer